Sandoz is offering a generic paclitaxel formulation, which is the first FDA-approved ANDA to BioScience’s Abraxane for Injectable Suspension (paclitaxel protein-bound particles for injectable ...

Sandoz paclitaxel protein-bound particles for injectable suspension (albumin-bound) was developed in partnership with Jiangsu Hengrui Pharmaceuticals Co., Ltd., and is the first FDA-approved ANDA ...

Sandoz has launched a generic paclitaxel formulation. It is the first generic of Abraxis BioScience’s (a Bristol Myers Squibb Co.) Abraxane to be approved by the Food and Drug Administration.

Sandoz US launches generic paclitaxel in single-dose vial, further expanding US oncology portfolio. News release. Sandoz. October 11, 2024.

Sandoz reports Q1 2025 net sales in line with company expectations; ... In North America, generics’ net-sales growth benefitted from the successful recent launch of paclitaxel. ...

First FDA-approved abbreviated new drug application (ANDA) to reference medicine Single-dose 100 mg vial for intravenous use, approved for metastatic breast cancer Launch expected to be near-term ...

Sandoz paclitaxel protein-bound particles for injectable suspension (albumin-bound) is indicated for the treatment of patients with metastatic breast cancer. The launch of the lyophilized powder for ...

Sandoz US Launches Generic Paclitaxel In Single-Dose Vial, Further Expanding US Oncology Portfolio ...

Princeton, NJ, October 11, 2024 – Sandoz, the global leader in generic and biosimilar medicines, today announced that it has launched a generic paclitaxel formulation in the US, the first generic to ...